Latest Period
Q4 2025
Security Snapshot
Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) Institutional Ownership
CUSIP: 83422E204
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
124
Shares (Excl. Options)
81,373,475
Price
$5.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- SLDB on Nasdaq
- Shares outstanding
- 92,783,558
- Price per share
- $8.02
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 81,373,475
- Total reported value
- $458,958,749
- % of total 13F portfolios
- 0%
- Share change
- +13,375
- Value change
- -$1,220,007
- Number of holders
- 124
- Price from insider filings
- $8.02
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SLDB - Solid Biosciences Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 83422E204.
- 124 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 124 to 15 between Q4 2025 and Q1 2026.
- Reported value moved from $458,958,749 to $4,402,133.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 124 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 83422E204?
CUSIP 83422E204 identifies SLDB - Solid Biosciences Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 83422E204:
Significant Owners of Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 13% | -17% | $82,945,717 | +$238,392 | 11,969,079 | +0.29% | Perceptive Advisors LLC | 09 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $66,971,007 | +$11,548,263 | 9,663,926 | +21% | RA Capital Management, L.P. | 06 Mar 2026 |
| Invus Global Management, LLC | 9.6% | +2.2% | $27,216,371 | +$13,457,391 | 7,415,905 | +98% | Raymond Debbane | 31 Mar 2025 |
| Vestal Point Capital, LP | 7.5% | +260% | $32,796,600 | +$22,906,533 | 5,815,000 | +232% | Vestal Point Capital, LP | 31 Dec 2025 |
| BlackRock, Inc. | 6.1% | $22,954,472 | 4,712,573 | BlackRock, Inc. | 30 Jun 2025 | |||
| Adage Capital Management, L.P. | 1.8% | -67% | $7,896,000 | -$14,664,000 | 1,400,000 | -65% | Adage Capital Management, L.P. | 31 Dec 2025 |
As of 31 Dec 2025, 124 institutional investors reported holding 81,373,475 shares of Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB). This represents 88% of the company’s total 92,783,558 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 13% | 11,833,539 | 0% | 1.2% | $66,741,160 |
| Bain Capital Life Sciences Investors, LLC | 8.5% | 7,911,669 | 0% | 3.4% | $44,621,813 |
| Siren, L.L.C. | 8.3% | 7,690,405 | +3.7% | 1.3% | $43,373,884 |
| Vestal Point Capital, LP | 6.3% | 5,815,000 | +95% | 1.2% | $32,796,600 |
| RA CAPITAL MANAGEMENT, L.P. | 6.3% | 5,811,423 | 0% | 0.34% | $32,776,426 |
| BlackRock, Inc. | 5.2% | 4,869,682 | +3.1% | 0% | $27,465,007 |
| VANGUARD GROUP INC | 3.7% | 3,454,959 | +12% | 0% | $19,485,969 |
| CITADEL ADVISORS LLC | 2.9% | 2,663,863 | +2.7% | 0.01% | $15,024,188 |
| ARMISTICE CAPITAL, LLC | 2.8% | 2,612,000 | +179% | 0.36% | $14,731,680 |
| Point72 Asset Management, L.P. | 2.6% | 2,416,108 | +81% | 0.02% | $13,626,849 |
| FMR LLC | 2.2% | 2,029,898 | -30% | 0% | $11,448,625 |
| Redmile Group, LLC | 2% | 1,860,542 | -2% | 0.77% | $10,493,457 |
| Alyeska Investment Group, L.P. | 1.8% | 1,682,805 | 0% | 0.03% | $9,491,020 |
| Nantahala Capital Management, LLC | 1.7% | 1,603,336 | -5.6% | 0.54% | $9,042,815 |
| FRANKLIN RESOURCES INC | 1.7% | 1,599,233 | +0% | 0% | $9,019,674 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.5% | 1,400,000 | -65% | 0.01% | $7,896,000 |
| Monashee Investment Management LLC | 1.5% | 1,349,771 | 4.3% | $7,612,708 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,267,392 | -1.5% | 0% | $7,149,537 |
| STATE STREET CORP | 1.2% | 1,087,413 | -0.54% | 0% | $6,133,009 |
| GOLDMAN SACHS GROUP INC | 1.1% | 1,006,306 | +49% | 0% | $5,675,566 |
| Finepoint Capital LP | 1% | 961,251 | 0% | 1% | $5,421,456 |
| UBS Group AG | 0.98% | 911,409 | +26% | 0% | $5,140,346 |
| Birchview Capital, LP | 0.76% | 705,955 | +138% | 2.3% | $3,981,586 |
| DIMENSIONAL FUND ADVISORS LP | 0.73% | 679,084 | +53% | 0% | $3,830,140 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.54% | 499,293 | -0.87% | 0% | $2,816,013 |
Institutional Holders of Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 611,407 | $4,402,133 | -$67,769 | $7.20 | 15 |
| 2025 Q4 | 81,373,475 | $458,958,749 | -$1,220,007 | $5.64 | 124 |
| 2025 Q3 | 81,357,999 | $501,971,186 | -$1,773,199 | $6.17 | 122 |
| 2025 Q2 | 82,208,819 | $400,360,815 | +$32,116,218 | $4.87 | 110 |
| 2025 Q1 | 78,846,500 | $291,701,746 | +$157,692,840 | $3.70 | 121 |
| 2024 Q4 | 36,331,707 | $145,326,212 | -$2,638,776 | $4.00 | 86 |
| 2024 Q3 | 35,844,916 | $249,839,838 | -$25,277,188 | $6.97 | 90 |
| 2024 Q2 | 37,594,933 | $213,228,886 | +$13,669,240 | $5.67 | 78 |
| 2024 Q1 | 34,987,922 | $465,886,559 | +$255,393,890 | $13.32 | 52 |
| 2023 Q4 | 16,633,699 | $102,223,957 | +$4,578,230 | $6.14 | 38 |
| 2023 Q3 | 16,169,847 | $40,746,223 | -$462,509 | $2.52 | 34 |
| 2023 Q2 | 16,340,241 | $85,622,446 | +$3,108,792 | $5.24 | 34 |
| 2023 Q1 | 15,773,407 | $74,764,734 | +$2,205,404 | $4.74 | 35 |
| 2022 Q4 | 15,014,401 | $80,763,090 | +$80,763,090 | $5.38 | 30 |
| 2020 Q4 | 0 | $0 | -$623,259 | $8.02 | 0 |
| 2020 Q3 | 307,024 | $623,259 | +$623,259 | $2.03 | 1 |